Cargando…

Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate

The participation of proinflammatory cytokines in the progression of Multiple Sclerosis (MS) has been well documented. Cytokines activate the JAK-STAT pathway, in which the suppressors of cytokine signaling (SOCS) exert a negative feedback. This paper analyzes the levels of SOCS5 and SOCS7 transcrip...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojas-Morales, Emmanuel, Santos-López, Gerardo, Hernández-Cabañas, Samuel, Arcega-Revilla, Raúl, Rosas-Murrieta, Nora, Jasso-Miranda, Carolina, El-Kassis, Elie Girgis, Reyes-Leyva, Julio, Sedeño-Monge, Virginia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982240/
https://www.ncbi.nlm.nih.gov/pubmed/31905601
http://dx.doi.org/10.3390/ijms21010218
_version_ 1783491269724471296
author Rojas-Morales, Emmanuel
Santos-López, Gerardo
Hernández-Cabañas, Samuel
Arcega-Revilla, Raúl
Rosas-Murrieta, Nora
Jasso-Miranda, Carolina
El-Kassis, Elie Girgis
Reyes-Leyva, Julio
Sedeño-Monge, Virginia
author_facet Rojas-Morales, Emmanuel
Santos-López, Gerardo
Hernández-Cabañas, Samuel
Arcega-Revilla, Raúl
Rosas-Murrieta, Nora
Jasso-Miranda, Carolina
El-Kassis, Elie Girgis
Reyes-Leyva, Julio
Sedeño-Monge, Virginia
author_sort Rojas-Morales, Emmanuel
collection PubMed
description The participation of proinflammatory cytokines in the progression of Multiple Sclerosis (MS) has been well documented. Cytokines activate the JAK-STAT pathway, in which the suppressors of cytokine signaling (SOCS) exert a negative feedback. This paper analyzes the levels of SOCS5 and SOCS7 transcripts, quantified by RT-qPCR, in MS patients, and the concentrations of proinflammatory cytokines, IFN-γ, IL17, and IL6, determined by ELISA. Samples of peripheral blood were obtained from MS patients in the relapsing–remitting phase, treated with IFN-β or glatiramer acetate (GA), and from healthy individuals. SOCS7 mRNA was significantly higher in patients treated with GA (1.36 ± 0.23) than in those treated with IFN-β (0.65 ± 0.1). Regarding gender, the level of SOCS5 and SOCS7 transcripts were similar between MS and healthy females; in MS males, the level of SOCS7 transcripts were significantly lower (0.59 ± 0.03) than in healthy males (1.008 ± 0.05). Plasmatic levels of IFN-γ were significantly higher in MS patients (60 pg/mL, range 0–160) than in healthy subjects (0 range, 0–106). The same pattern was observed in MS patients treated with IFN-β (68 pg/mL, range 0–160) compared to patients treated with GA (51 pg/mL, range 0–114), and in MS females (64 pg/mL, range 0–161) compared to healthy females (0, range 0–99). We hypothesize that the increase in SOCS7 transcription in patients treated with GA could partially explain the action mechanism of this drug, while the increase in the concentration of IFN-γ in MS patients could help elucidate the immunopathology of the disease.
format Online
Article
Text
id pubmed-6982240
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69822402020-02-07 Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate Rojas-Morales, Emmanuel Santos-López, Gerardo Hernández-Cabañas, Samuel Arcega-Revilla, Raúl Rosas-Murrieta, Nora Jasso-Miranda, Carolina El-Kassis, Elie Girgis Reyes-Leyva, Julio Sedeño-Monge, Virginia Int J Mol Sci Article The participation of proinflammatory cytokines in the progression of Multiple Sclerosis (MS) has been well documented. Cytokines activate the JAK-STAT pathway, in which the suppressors of cytokine signaling (SOCS) exert a negative feedback. This paper analyzes the levels of SOCS5 and SOCS7 transcripts, quantified by RT-qPCR, in MS patients, and the concentrations of proinflammatory cytokines, IFN-γ, IL17, and IL6, determined by ELISA. Samples of peripheral blood were obtained from MS patients in the relapsing–remitting phase, treated with IFN-β or glatiramer acetate (GA), and from healthy individuals. SOCS7 mRNA was significantly higher in patients treated with GA (1.36 ± 0.23) than in those treated with IFN-β (0.65 ± 0.1). Regarding gender, the level of SOCS5 and SOCS7 transcripts were similar between MS and healthy females; in MS males, the level of SOCS7 transcripts were significantly lower (0.59 ± 0.03) than in healthy males (1.008 ± 0.05). Plasmatic levels of IFN-γ were significantly higher in MS patients (60 pg/mL, range 0–160) than in healthy subjects (0 range, 0–106). The same pattern was observed in MS patients treated with IFN-β (68 pg/mL, range 0–160) compared to patients treated with GA (51 pg/mL, range 0–114), and in MS females (64 pg/mL, range 0–161) compared to healthy females (0, range 0–99). We hypothesize that the increase in SOCS7 transcription in patients treated with GA could partially explain the action mechanism of this drug, while the increase in the concentration of IFN-γ in MS patients could help elucidate the immunopathology of the disease. MDPI 2019-12-28 /pmc/articles/PMC6982240/ /pubmed/31905601 http://dx.doi.org/10.3390/ijms21010218 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rojas-Morales, Emmanuel
Santos-López, Gerardo
Hernández-Cabañas, Samuel
Arcega-Revilla, Raúl
Rosas-Murrieta, Nora
Jasso-Miranda, Carolina
El-Kassis, Elie Girgis
Reyes-Leyva, Julio
Sedeño-Monge, Virginia
Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate
title Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate
title_full Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate
title_fullStr Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate
title_full_unstemmed Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate
title_short Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate
title_sort differential transcription of socs5 and socs7 in multiple sclerosis patients treated with interferon beta or glatiramer acetate
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982240/
https://www.ncbi.nlm.nih.gov/pubmed/31905601
http://dx.doi.org/10.3390/ijms21010218
work_keys_str_mv AT rojasmoralesemmanuel differentialtranscriptionofsocs5andsocs7inmultiplesclerosispatientstreatedwithinterferonbetaorglatirameracetate
AT santoslopezgerardo differentialtranscriptionofsocs5andsocs7inmultiplesclerosispatientstreatedwithinterferonbetaorglatirameracetate
AT hernandezcabanassamuel differentialtranscriptionofsocs5andsocs7inmultiplesclerosispatientstreatedwithinterferonbetaorglatirameracetate
AT arcegarevillaraul differentialtranscriptionofsocs5andsocs7inmultiplesclerosispatientstreatedwithinterferonbetaorglatirameracetate
AT rosasmurrietanora differentialtranscriptionofsocs5andsocs7inmultiplesclerosispatientstreatedwithinterferonbetaorglatirameracetate
AT jassomirandacarolina differentialtranscriptionofsocs5andsocs7inmultiplesclerosispatientstreatedwithinterferonbetaorglatirameracetate
AT elkassiseliegirgis differentialtranscriptionofsocs5andsocs7inmultiplesclerosispatientstreatedwithinterferonbetaorglatirameracetate
AT reyesleyvajulio differentialtranscriptionofsocs5andsocs7inmultiplesclerosispatientstreatedwithinterferonbetaorglatirameracetate
AT sedenomongevirginia differentialtranscriptionofsocs5andsocs7inmultiplesclerosispatientstreatedwithinterferonbetaorglatirameracetate